• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

DEA moves to reschedule buprenorphine

July 1, 2002
Jennifer Fiala

Government to impose stricter regulatory controls for drug due to abuse potential

Washington-Based on reports of widespread European abuse, Drug Enforcement Agency (DEA) officials moved to reschedule the pain reliever buprenorphine before the U.S. Food and Drug Administration (FDA) approves a potent tablet version for U.S. use.

This long lasting analgesic approved for off-label use by veterinarianscurrently is available in low doses in an injectable form. Acting on a formalrequest by the Department of Health and Human Services, DEA aims to upgradethe semi-synthetic narcotic from a Schedule V to Schedule III drug.

On the human side, buprenorphine treats heroin and cocaine addiction.

Affecting the veterinarian?

As far as obtaining buprenorphine, its reschedule, at most, might meanmore paperwork for the DEA-licensed DVM.

Government officials note that buprenorphine produces effects similarto other pure mu agonists, including euphoria, drug liking, respiratorydepression, pupillary constriction and sedation.

Although little abuse or theft of buprenorphine is noted in the UnitedStates, significant abuse has been reported in countries where strongerversions are marketed. In France, for example, the drug's overdose has resultedin more than 100 deaths.

On the eve of its more potent introduction into the United States' drugmarket, DEA officials warn that, "Buprenorphine products have beendiverted from legitimate channels through theft, doctor shopping and fraudulentprescriptions."

"The drug doesn't have a wide distribution in the U.S. right now,"says Pat Clarke, spokesperson for the DEA's Center for Drug Evaluation andResearch, "but when the tablet version does get abused, that abuseis sure to run rampant."

Narcotics

Classifications

Advertisement

Schedule V

* The drug has a low potential for abuse relative to drugs inother schedules.

* The drug has currently accepted medical use in treatment inthe United States.

* Abuse of the drug or other substance may lead to limited physicaldependence or psychological dependence relative to drugs in other schedules.

Schedule III

* The drug has a potential for abuse less than drugs or othersubstances in schedules I and II.

* The drug has a currently accepted medical use in treatment inthe United States.

* Abuse of the drug or other substance may lead to moderate orlow physical dependence or high psychological dependence.

Source: DEA

Related Content:

Regulatory
USDA aims to strengthen handling regulations for exotic animals in exhibition
USDA aims to strengthen handling regulations for exotic animals in exhibition
What you need to know about GFI #256 and the changing landscape of compounding medicine
What you need to know about GFI #256 and the changing landscape of compounding medicine
3 common misconceptions in controlled substance regulations
3 common misconceptions in controlled substance regulations

Advertisement

Latest News

Proper praise for a flourishing team environment

Chronic feline pain from all perspectives

Veterinary training to expand in Ontario with government investment

Pet Advocacy Network honors outstanding contributions to the pet care community

View More Latest News
Advertisement